American Journal of Cardiovascular Drugs 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Do Oral Factor Xa Inhibitors have a Role in Patients with Mechanical Heart Valves?
AbstractMechanical heart valves (MHVs) replacement is recommended for younger patients with valvular heart disease because of the durability of the mechanical valve, but these patients need antithrombotic therapy for a lifelong time. The vitamin K antagonist (VKA) warfarin is the only approved oral antithrombotic drug for patients with MHVs. The direct oral anticoagulants (DOACs), including direct thrombin inhibitors and factor Xa (FXa) inhibitors, present some advantages over warfarin, such as weak interaction with drugs, no need for routine monitoring of coagulation function, and no frequent adjustment of medication dose...
Source: American Journal of Cardiovascular Drugs - July 23, 2022 Category: Cardiology Source Type: research
Aspirin with Low-Dose Ticagrelor or with Low-Dose Rivaroxaban for Secondary Prevention: A Cost per Outcome Analysis
ConclusionCombining aspirin with LD rivaroxaban provides better value for money than with LD ticagrelor for secondary prevention of MACE. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - July 23, 2022 Category: Cardiology Source Type: research
Cost-Utility Analysis of Combination Empagliflozin and Standard Treatment Versus Standard Treatment Alone in Thai Heart Failure Patients with Reduced or Preserved Ejection Fraction
ConclusionsAt the local Thai threshold of 4773.27 USD/QALY, empagliflozin is a cost-effective add-on treatment for patients with HFrEF, but not for patients with HFpEF. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - July 7, 2022 Category: Cardiology Source Type: research
Abbreviated versus Standard Duration of DAPT after PCI: A Systematic Review and Network Meta-analysis
ConclusionThe results support the growing body of evidence that abbreviated duration (1 –3 months) of DAPT may be considered to reduce the risk of bleeding without any differences in myocardial infarction, stent thrombosis, or MACE. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - July 4, 2022 Category: Cardiology Source Type: research
Safety and Effectiveness of Direct Oral Anticoagulants Versus Warfarin for Treating Left Ventricular Thrombus
ConclusionsIn this diverse population-based cohort of patients, DOAC treatment for left ventricular thrombus appears to be as safe and effective as warfarin treatment. These findings support the use of DOACs for patients with left ventricular thrombus. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - July 1, 2022 Category: Cardiology Source Type: research
Comparison of Efficacy and Safety of Statin –Ezetimibe Combination Therapy with Statin Monotherapy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Studies
ConclusionsStatin –ezetimibe combination therapy enhances levels of LDL-C and other lipids without increasing the risk of adverse events compared with statin monotherapy. The present meta-analysis presents valid evidence for appropriate drug regimens to treat dyslipidemia in patients with diabetes.RegistrationPROSPERO Identifier Number CRD42021244578 (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - July 1, 2022 Category: Cardiology Source Type: research
Effectiveness and Safety of Rivaroxaban versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Polypharmacy
ConclusionsIn this real-world study of NVAF patients with obesity, rivaroxaban was associated with lower risks of stroke and systemic embolism and similar risk of major bleeding versus warfarin across polypharmacy categories. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - July 1, 2022 Category: Cardiology Source Type: research
A Comprehensive Approach to Managing Methamphetamine-Associated Cardiomyopathy
AbstractMethamphetamines are illicit drugs of the amphetamine-type stimulant class that have been increasing in popularity, availability, and purity in recent decades. As a result, rates of methamphetamine-associated cardiomyopathy (MAC) are rising globally. MAC is associated with high rates of sudden cardiac arrest, late presentation, and poor outcomes. This review discusses the medical management of MAC, including anticipated challenges specific to methamphetamine users. Not only are patients with MAC more likely to present at a younger age and with multisystem disease than patients with cardiomyopathy of other etiologie...
Source: American Journal of Cardiovascular Drugs - July 1, 2022 Category: Cardiology Source Type: research
Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Cardiovascular Disease: The Past, Present, and Future
AbstractType 2 diabetes mellitus (T2DM) is associated with high cardiovascular morbidity and mortality, and cardiovascular diseases are the leading causes of death and disability in people with T2DM. Unfortunately, therapies strictly aimed at glycemic control have poorly contributed to a significant reduction in the risk of cardiovascular events. On the other hand, randomized controlled trials have shown that five glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and one exendin-based GLP-1 RA reduced atherosclerotic cardiovascular events in patients with diabetes at high cardiovascular risk. Furthermore, a meta-analys...
Source: American Journal of Cardiovascular Drugs - July 1, 2022 Category: Cardiology Source Type: research
A Horse, a Jockey, and a Therapeutic Dilemma: Choosing the Best Option for a Patient with Diabetes and Coronary Artery Disease
AbstractCurrent guidelines for the management of hyperglycemia recommend the use of agents with proven cardiovascular (CV) benefit in patients with type 2 diabetes (T2D) and established CV disease. Although both glucagon-like peptide 1 receptor agonists (GLP-1 RA) and sodium-glucose co-transporter 2 inhibitors (SGLT2i) have been shown to reduce the risk of major adverse CV events (MACE) in high-risk populations with T2D, the ideal choice between the two classes for people with coronary artery disease remains controversial. SGLT2i reduce CV risk primarily through hemodynamic effects and changes in energy metabolism, making ...
Source: American Journal of Cardiovascular Drugs - July 1, 2022 Category: Cardiology Source Type: research
Comparison of Direct Oral Anticoagulants for Acute Hospital Mortality in Venous Thromboembolism
ConclusionOn PS-matched analysis, there was a difference in in-hospital mortality, especially in the rivaroxaban and apixaban group. Identifying the clinical characteristics of patients associated with each DOAC, as well as prognosis, will be useful in determining treatment strategies for VTE. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - July 1, 2022 Category: Cardiology Source Type: research
Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy
ConclusionsIn patients with ATTR-CM, tafamidis was associated with a lower rate of CV-related hospitalizations and shorter length of hospital stay. Timely diagnosis and treatment with tafamidis could further decrease the total number of CV-related hospitalization days per year.CLINICALTRIALS.gov IdentifierNCT01994889. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - July 1, 2022 Category: Cardiology Source Type: research
A Multicenter Retrospective Evaluation of Direct Oral Anticoagulants for the Treatment of Heparin-Induced Thrombocytopenia
ConclusionIn this retrospective cohort study, DOACs were associated with rates of thrombotic and hemorrhagic events similar to those with other therapies currently used in the treatment of HIT. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - July 1, 2022 Category: Cardiology Source Type: research
